Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OSI-906 and Erlotinib with Endocrine Therapy in Metastatic Breast Cancer
NCT01205685Phase 2Terminated
- Sponsor
- Vanderbilt-Ingram Cancer Center
- Start
- May 2010
- Primary completion
- Jul 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of linsitinib in breast cancer, sponsored by Vanderbilt-Ingram Cancer Center. Started May 2010; status: terminated.
02
Drugs
linsitinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01205685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01205685.